Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extrapyramidal symptoms in patients treated with risperidone

G M Simpson1, J P Lindenmayer

  • 1Department of Psychiatry and Behavioral Sciences, University of Southern California School of Medicine, LAC/USC Medical Center 90033-1071, USA.

Journal of Clinical Psychopharmacology
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tardive dyskinesia versus tardive syndrome. What is in a name?

Parkinsonism & related disorders·2025
Same author

Effects of Clozapine on Neurocognitive Functions in Schizophrenia: A Naturalistic Comparison to Non-clozapine Antipsychotics.

Innovations in clinical neuroscience·2022
Same author

Transcranial direct-current stimulation in ultra-treatment-resistant schizophrenia.

Brain stimulation·2018
Same author

The relationship of cognitive improvement after cognitive remediation with social functioning in patients with schizophrenia and severe cognitive deficits.

Schizophrenia research·2017
Same author

Abscisic acid associated with wilting in dwarf and tall Pisum sativum.

Planta·2014
Same author

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.

Schizophrenia research·2013

Low doses of risperidone cause minimal extrapyramidal symptoms (EPS) in schizophrenia patients compared to haloperidol. Even high risperidone doses showed fewer EPS, suggesting a favorable safety profile for risperidone.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Neuroscience

Background:

  • Extrapyramidal symptoms (EPS) are a significant concern with antipsychotic medications.
  • Risperidone is an atypical antipsychotic used for schizophrenia, but its EPS profile requires detailed evaluation.
  • Haloperidol is a typical antipsychotic often associated with pronounced EPS.

Purpose of the Study:

  • To compare the incidence and severity of EPS between risperidone, placebo, and haloperidol in patients with chronic schizophrenia.
  • To assess the dose-dependent relationship between risperidone and EPS.
  • To identify risk factors for developing EPS during antipsychotic treatment.

Main Methods:

  • Analysis of data from a North American multicenter comparative study involving 523 schizophrenia patients.

Related Experiment Videos

  • Randomized treatment with placebo, risperidone (2-16 mg/day), or haloperidol (20 mg/day) for 8 weeks.
  • Assessment of EPS severity using the Extrapyramidal Symptom Rating Scale (ESRS).

    • Main Results:

    • Each risperidone group showed significantly lower mean increases in total ESRS scores compared to haloperidol (p < 0.001).
    • Some risperidone doses resulted in significantly lower subscale scores than placebo (p < 0.05), particularly for dyskinesia.
    • A dose-dependent relationship between risperidone and EPS was observed, but even at 16 mg/day, EPS were lower than with haloperidol.

    Conclusions:

    • Low doses of risperidone are associated with few or no extrapyramidal symptoms.
    • Risperidone appears to have a more favorable EPS profile than haloperidol, even at higher doses.
    • Recommendations for initiating risperidone treatment should consider dose titration to minimize potential EPS.